Paul Hagopian, Chief Growth Officer, Fingerpaint Group
Advertisement
Articles by Paul Hagopian, Chief Growth Officer, Fingerpaint Group
Advertisement
Latest Updated Articles
- The opportunity to evolve the oncology model is ready and waiting
Published: June 1st 2023 | Updated:
Advertisement
Advertisement
Trending on PharmExec
1
JP Morgan 2026: AbbVie Advances its Pipeline
2
Pharmaceutical Executive Daily: Continued Coverage of the 2026 J.P. Morgan Healthcare Conference
3
Pharmaceutical Executive Daily: 2026 J.P. Morgan Healthcare Conference Coverage
4
JP Morgan 2026: Novavax Shifting Towards Partnership-Driven Strategy
5